GlaxoSmithKline Submits New Application for Synflorix in EU

GlaxoSmithKline PLC (GSK.LN), a research-based pharmaceutical and healthcare company, said Monday it has submitted a regulatory application in the European Union, or E.U., seeking approval of an additional indication for Synflorix(TM), a paediatric pneumococcal vaccine, for the active immunization against pneumonia caused by Streptococcus pneumoniae in infants and children from six weeks up to five years of age. Application was submitted as a variation to the Marketing Authorization Application to the European Medicines Agency.